Skip to main content
Erschienen in: Nuclear Medicine and Molecular Imaging 2/2015

01.06.2015 | Case Report

Changes in Skeletal Tumor Activity on 18F-choline PET/CT in Patients Receiving 223Radium Radionuclide Therapy for Metastatic Prostate Cancer

verfasst von: Kyle S. Miyazaki, Yu Kuang, Sandi A. Kwee

Erschienen in: Nuclear Medicine and Molecular Imaging | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Radium-223 dichloride is an alpha-emitting radiopharmaceutical shown to prolong survival in patients with castrate-resistant prostate cancer (CRPC) and symptomatic skeletal metastases. This report describes in two patients the acute changes in bone metastatic activity detected by F-18 choline PET/CT imaging midway during treatment with radium-223 dichloride. In addition to visual and standardized uptake value analysis, changes in the whole-body tumor burden were quantified by measuring the difference in net metabolically active tumor volume (MATV) and total lesion activity (TLA) between pre- and mid-treatment PET scans. After the third dose of radium-223 dichloride, near-total disappearance of abnormal skeletal activity was observed in one case (net MATV change from 260.7 to 0.8 cc; net TLA change from 510.7 to 2.1), while a heterogeneous tumor response was observed in the other (net MATV change from 272.2 to 241.3 cc; net TLA change from 987.1 to 779.4). Corresponding normalization and persistent elevation in serum alkaline phosphatase levels were observed in these cases, respectively. Further research is needed to determine the predictive value of serial F-18 choline PET/CT imaging in patients receiving radium-223 dichloride for CRPC.
Literatur
1.
Zurück zum Zitat Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–23.CrossRefPubMed Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–23.CrossRefPubMed
2.
Zurück zum Zitat Schoder H, Herrmann K, Gonen M, Hricak H, Eberhard S, Scardino P, et al. 2-[18 F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res: Off J Am Assoc Cancer Res. 2005;11(13):4761–9.CrossRef Schoder H, Herrmann K, Gonen M, Hricak H, Eberhard S, Scardino P, et al. 2-[18 F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res: Off J Am Assoc Cancer Res. 2005;11(13):4761–9.CrossRef
3.
Zurück zum Zitat Glunde K, Jacobs MA, Bhujwalla ZM. Choline metabolism in cancer: implications for diagnosis and therapy. Expert Rev Mol Diagn. 2006;6(6):821–9.CrossRefPubMed Glunde K, Jacobs MA, Bhujwalla ZM. Choline metabolism in cancer: implications for diagnosis and therapy. Expert Rev Mol Diagn. 2006;6(6):821–9.CrossRefPubMed
4.
Zurück zum Zitat Price DT, Coleman RE, Liao RP, Robertson CN, Polascik TJ, DeGrado TR. Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol. 2002;168(1):273–80.CrossRefPubMed Price DT, Coleman RE, Liao RP, Robertson CN, Polascik TJ, DeGrado TR. Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol. 2002;168(1):273–80.CrossRefPubMed
5.
Zurück zum Zitat Kwee SA, Lim J, Watanabe A, Kromer-Baker K, Coel MN. Prognosis related to metastatic burden measured by 18 F-fluorocholine PET/CT in castration-resistant prostate cancer. J Nucl Med: Off Publ Soc Nucl Med. 2014;55(6):905–10.CrossRef Kwee SA, Lim J, Watanabe A, Kromer-Baker K, Coel MN. Prognosis related to metastatic burden measured by 18 F-fluorocholine PET/CT in castration-resistant prostate cancer. J Nucl Med: Off Publ Soc Nucl Med. 2014;55(6):905–10.CrossRef
6.
Zurück zum Zitat Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.CrossRefPubMed Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.CrossRefPubMed
7.
Zurück zum Zitat Sonpavde G, Pond GR, Berry WR, de Wit R, Armstrong AJ, Eisenberger MA, et al. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urol Oncol. 2012;30(5):607–13.CrossRefPubMed Sonpavde G, Pond GR, Berry WR, de Wit R, Armstrong AJ, Eisenberger MA, et al. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urol Oncol. 2012;30(5):607–13.CrossRefPubMed
8.
Zurück zum Zitat Balogova S, Huchet V, Egrot C, Michaud L, Paycha F, Kerrou K, et al. Effect of erythropoietin on bone marrow uptake of 18 F-fluorocholine in prostate cancer: comparison with 18 F-fluoride uptake. Clin Nucl Med. 2013;38(3):200–2.CrossRefPubMed Balogova S, Huchet V, Egrot C, Michaud L, Paycha F, Kerrou K, et al. Effect of erythropoietin on bone marrow uptake of 18 F-fluorocholine in prostate cancer: comparison with 18 F-fluoride uptake. Clin Nucl Med. 2013;38(3):200–2.CrossRefPubMed
Metadaten
Titel
Changes in Skeletal Tumor Activity on 18F-choline PET/CT in Patients Receiving 223Radium Radionuclide Therapy for Metastatic Prostate Cancer
verfasst von
Kyle S. Miyazaki
Yu Kuang
Sandi A. Kwee
Publikationsdatum
01.06.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Nuclear Medicine and Molecular Imaging / Ausgabe 2/2015
Print ISSN: 1869-3474
Elektronische ISSN: 1869-3482
DOI
https://doi.org/10.1007/s13139-014-0314-0

Weitere Artikel der Ausgabe 2/2015

Nuclear Medicine and Molecular Imaging 2/2015 Zur Ausgabe